Evidence map›Paper›PMID 36775929›Full record

ArticleCancer medicine2023

Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes.

Mamdouh N Aker, Wayne G Brisbane, Lorna Kwan, Samantha Gonzalez, Alan M Priester, Adam Kinnaird, Merdie K Delfin, Ely Felker, Anthony E Sisk, David Kuppermann and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. MR Imaging/Ultrasound Fusion-Guided Biopsy and Primary Focal Therapy for Localized Prostate Cancer.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Three-dimensional spatial localization and volume estimation of prostate tumors usingEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  10. Article
  11. Current Status of Cryoablation in Prostate Cancer Management.Clinical Medicine Insights. Oncology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Mamdouh N AkerDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.ORCID 0000-0003-4036-2754
Wayne G BrisbaneDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Lorna KwanDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Samantha GonzalezDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Alan M PriesterAvenda Health, Culver City, California, USA.
Adam KinnairdDepartment of Urology, University of Alberta, Edmonton, Alberta, USA.
Merdie K DelfinDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Ely FelkerDepartment of Radiology, David Geffen School of Medicine at University of California, Los Angeles.
Anthony E SiskDepartment of Pathology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
David KuppermannDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
Leonard S MarksDepartment of Urology, David Geffen School of Medicine at University of California, Los Angeles, California, USA.
University of California, Los Angeles · USStanford Health Care · USUniversity of Alberta · CA

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
Prospective Assessment of Image Registration for the Diagnosis of Prostate CancerR01CA195505 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARKS, LEONARD STEPHEN · 2015 to 2016
$705k
NCATS NIH HHS UL1 TR000124NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA195505NCI NIH HHS R01CA195505
6 · The paper itself

Abstract

backgroundPartial gland ablation (PGA) is a new option for treatment of prostate cancer (PCa). Cryotherapy, an early method of PGA, has had favorable evaluations, but few studies have employed a strict protocol using biopsy endpoints in men with clinically significant prostate cancer (csPCa).

methods143 men with unilateral csPCa were enrolled in a prospective, observational trial of outpatient PGA-cryotherapy. Treatment was a 2-cycle freeze of the affected prostate part. Participants were evaluated with MRI-guided biopsy (MRGB) at baseline and at 6 months and 18 months after treatment. Absence of csPCa upon MRGB was the primary endpoint; quality-of-life at baseline and at 6 months after treatment was assessed by EPIC-CP questionnaires in the domains of urinary and sexual function.

resultsOf the 143 participants, 136 (95%) completed MRGB at 6 months after treatment. In 103/136 (76%), the biopsy revealed no csPCa. Of the 103, 71 subsequently had an 18-month comprehensive biopsy; of the 71 with 18-month biopsies, 46 (65%) were found to have no csPCa. MRI lesions became undetectable in 96/130 (74%); declines in median serum PSA levels (6.9 to 2.5 ng/mL), PSA density (0.15 to 0.07), and prostate volume (42 to 34cc) were observed (all p < 0.01). Neither lesion disappearance on MRI nor PSA decline correlated with biopsy outcome. Urinary function was affected only slightly and sexual function moderately.

conclusionIn the near to intermediate term, partial gland ablation with cryotherapy was found to be a safe and moderately effective treatment of intermediate-risk prostate cancer. Eradication of cancer was better determined by MRI-guided biopsy than by MRI or PSA.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsCryotherapyHumansImage-Guided BiopsyMagnetic Resonance ImagingMaleProspective StudiesProstate-Specific Antigencryotherapyfocal therapyProstate cancer

Identifiers

PMID36775929
PMCPMC10166973
OpenAlexW4320495590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.